Skip to content
Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to improve treatment outcomes for children and adults with cancer
Clarity Pharmaceuticals - Radiopharmaceutical Therapies and ImagingClarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube

Daily Archives: July 28, 2025

Clarity successfully completes $203 million institutional placement

News, Press ReleasesBy India Broom WaughJuly 28, 2025

Sydney, Australia 28 July 2025 Highlights Clarity has successfully completed a $203 million Placement with a small group of institutional investors who are close to the Company. The issue price of the Placement is $4.20 per share, which represents a 2.2% premium to Clarity’s previous closing price and an 18.0% premium to Clarity’s 15-day Volume…

Go to Top